NasdaqCM - Nasdaq Real Time Price USD

Abeona Therapeutics Inc. (ABEO)

Compare

4.8400

-0.0100

(-0.21%)

At close: April 17 at 4:00:01 PM EDT

4.9796

+0.14

+(2.88%)

After hours: April 17 at 5:31:23 PM EDT

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CLEVELAND, April 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On March 31, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to six individuals hired by Abeona, which equity awards relate to, in the ag

GlobeNewswire 17 days ago

ABEO
-0.21%
ABEO: Countdown to PDUFA Date of April 29, 2025…

By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update Countdown to Apr. 29, 2025 PDUFA for pz-cel Abeona Therapeutics, Inc. (NASDAQ:ABEO) is continuing preparations for the potential commercial launch of prademagene zamikeracel (pz-cel), which has a PDUFA target action date of April 29, 2025. The company resubmitted the Biologics License Application (BLA) following

Zacks Small Cap Research 25 days ago

ABEO
-0.21%
Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

Abeona Therapeutics Inc (ABEO) reports strong cash reserves and anticipates FDA approval for its promising treatment, pz-cel, despite initial supply constraints.

GuruFocus.com 28 days ago

ABEO
-0.21%
Q4 2024 Abeona Therapeutics Inc Earnings Call

Q4 2024 Abeona Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 28 days ago

ABEO
-0.21%
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025 Launch preparations on track toward goal to treat first patient in 3Q 2025 CLEVELAND, March 20, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the full year of 2024, and announced progress in the ongoing review with the U.S. Food and Drug Administration (FDA) regarding prademagene zami

GlobeNewswire 29 days ago

ABEO
-0.21%
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

CLEVELAND, March 04, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Abeona’s Chief Executive Officer, Vish Seshadri, Ph.D., M.B.A., will present at the Leerink Partners Global Healthcare Conference in Miami, Florida on Monday, March 10, 2025 at 3:00 p.m. Eastern Time. A live webcast of the presentation can be accessed on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events. The webcast will be archive

GlobeNewswire last month

ABEO
-0.21%
Abeona Therapeutics announces new employee inducement grants

Abeona Therapeutics (ABEO) has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). On February 28, 2025, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 16,300 restricted shares of Abeona common stock. One-third

TipRanks last month

ABEO
-0.21%
Abeona Therapeutics Inc.'s (NASDAQ:ABEO) Shift From Loss To Profit

We feel now is a pretty good time to analyse Abeona Therapeutics Inc.'s ( NASDAQ:ABEO ) business as it appears the...

Simply Wall St. 2 months ago

ABEO
-0.21%
Owning 43% shares,institutional owners seem interested in Abeona Therapeutics Inc. (NASDAQ:ABEO),

Key Insights Significantly high institutional ownership implies Abeona Therapeutics' stock price is sensitive to their...

Simply Wall St. 3 months ago

ABEO
-0.21%
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 /DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a ...

ACCESS Newswire 4 months ago

ASNS

BETR

BETRW
ABEO: FDA Accepts BLA Re-Submission for Pz-cel; PDUFA Date of April 29, 2025; Raising Valuation to $9.50…

By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update BLA Resubmission Accepted; PDUFA Date of April 29, 2025 On November 12, 2024, Abeona Therapeutics, Inc. (NASDAQ:ABEO) announced that the U.S. FDA has accepted the Biologics License Application (BLA) for prademagene zamikeracel (pz-cel) and set a PDUFA target action date of April 29, 2025. The resubmission of the

Zacks Small Cap Research 4 months ago

ABEO
-0.21%
Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Abeona Therapeutics Inc (ABEO) navigates regulatory hurdles and competition while preparing for the commercial launch of its innovative therapy.

GuruFocus.com 4 months ago

ABEO
-0.21%
Abeona Therapeutics: Q3 Earnings Snapshot

CLEVELAND (AP) — Abeona Therapeutics Inc. ABEO) on Thursday reported a loss of $20.3 million in its third quarter. On a per-share basis, the Cleveland-based company said it had a loss of 42 cents.

Associated Press Finance 5 months ago

ABEO
-0.21%
Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

FDA accepts BLA resubmission of pz-cel in recessive dystrophic epidermolysis bullosa and sets PDUFA target action date of April 29, 2025 Company makes significant progress toward potential commercialization of pz-cel in 2025; Builds momentum with payor discussions and target treatment centers CLEVELAND, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the third quarter ended September 30, 2024, and recent corporate updates. “With the

GlobeNewswire 5 months ago

ABEO
-0.21%
Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

FDA assigns PDUFA target action date of April 29, 2025CLEVELAND, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Abeona’s resubmission of its Biologics License Application (BLA) for prademagene zamikeracel (pz-cel), its investigational autologous cell-based gene therapy, as a potential new treatment for recessive dystrophic epidermolysis bullosa (RDEB). The FDA has assigned a Prescr

GlobeNewswire 5 months ago

ABEO
-0.21%
Abeona Therapeutics® Announces Participation in November Investor Conferences

CLEVELAND, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November 2024: Truist Securities BioPharma Symposium: Investor meetings on Thursday, November 7, 2024.Stifel 2024 Healthcare Conference: Fireside chat on Monday, November 18, 2024 at 4:10 p.m. ET and investor meetings. A live webcast of the fireside chat can be accessed on the Investors section of the Abeona

GlobeNewswire 5 months ago

ABEO
-0.21%
Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

CLEVELAND, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company has resubmitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA or Agency) for prademagene zamikeracel (pz-cel), its investigational autologous cell-based gene therapy, as a potential new treatment for patients with recessive dystrophic epidermolysis bullosa (RDEB). “We have worked closely with the FDA in preparing for the pz-cel BLA resubmis

GlobeNewswire 5 months ago

ABEO
-0.21%
Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...

Abeona Therapeutics Inc (ABEO) reports a net income boost and strategic progress, despite challenges in BLA resubmission timeline.

GuruFocus.com 6 months ago

ABEO
-0.21%
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

CLEVELAND, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2024: Wells Fargo Healthcare Conference: Investor meetings on Thursday, September 5, 2024.H.C. Wainwright Annual Global Investment Conference: Company presentation on Tuesday, September 10, 2024 at 1:30 p.m. ET and investor meetings.Cantor Global Healthcare Conference: Fireside chat on Thursday, Se

GlobeNewswire 7 months ago

ABEO
-0.21%
ABEO: Type A Meeting with FDA Concluded; BLA Submission on Track for 2H24…

By David Bautz, PhD NASDAQ:ABEO READ THE FULL ABEO RESEARCH REPORT Business Update Type A Meeting with FDA Complete; BLA Resubmission in 2H24 Abeona Therapeutics, Inc. (NASDAQ:ABEO) is currently working on the resubmission of the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Recently, Abeona

Zacks Small Cap Research 7 months ago

ABEO
-0.21%

Performance Overview

Return	ABEO	S&P 500 (^GSPC)
YTD	-13.11%	-10.18%
1-Year	-38.97%	+5.19%
3-Year	-28.30%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Abeona Therapeutics Inc. (ABEO)

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ABEO: Countdown to PDUFA Date of April 29, 2025…

Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ...

Q4 2024 Abeona Therapeutics Inc Earnings Call

Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans

Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference

Abeona Therapeutics announces new employee inducement grants

Abeona Therapeutics Inc.'s (NASDAQ:ABEO) Shift From Loss To Profit

Owning 43% shares,institutional owners seem interested in Abeona Therapeutics Inc. (NASDAQ:ABEO),

DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ABEO: FDA Accepts BLA Re-Submission for Pz-cel; PDUFA Date of April 29, 2025; Raising Valuation to $9.50…

Abeona Therapeutics Inc (ABEO) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Abeona Therapeutics: Q3 Earnings Snapshot

Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa

Abeona Therapeutics® Announces Participation in November Investor Conferences

Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration

Abeona Therapeutics Inc (ABEO) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

ABEO: Type A Meeting with FDA Concluded; BLA Submission on Track for 2H24…

Performance Overview